RAPT Therapeutics pivoted from a failed inflammation asset (RPT193) to focus on RPT904 for food allergies. RPT904, an IgE-inhibiting mAb licensed from Jemincare, is in Phase 2 for food allergy, CSU, ...
RAPT Therapeutics, Inc. (NASDAQ:RAPT – Get Free Report) has been assigned an average recommendation of “Hold” from the nine ratings firms that are currently covering the stock, MarketBeat reports. One ...
Trial initiation in food allergy follows promising results in Phase 2 trial in chronic spontaneous urticaria, another IgE-driven condition RAPT seeks to develop a differentiated anti-IgE therapy for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback